-
2
-
-
1942422646
-
Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease
-
Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004, 10:396-401.
-
(2004)
Nat Med
, vol.10
, pp. 396-401
-
-
Passage, E.1
Norreel, J.C.2
Noack-Fraissignes, P.3
-
3
-
-
71049172916
-
Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial
-
Verhamme C, de Haan RJ, Vermeulen M, et al. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med 2009, 7:70.
-
(2009)
BMC Med
, vol.7
, pp. 70
-
-
Verhamme, C.1
de Haan, R.J.2
Vermeulen, M.3
-
4
-
-
65549159213
-
Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial
-
Burns J, Ouvrier RA, Yiu EM, et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009, 8:537-544.
-
(2009)
Lancet Neurol
, vol.8
, pp. 537-544
-
-
Burns, J.1
Ouvrier, R.A.2
Yiu, E.M.3
-
5
-
-
72149100190
-
Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial
-
Micallef J, Attarian S, Dubourg O, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2009, 8:1103-1110.
-
(2009)
Lancet Neurol
, vol.8
, pp. 1103-1110
-
-
Micallef, J.1
Attarian, S.2
Dubourg, O.3
-
6
-
-
79952736703
-
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial
-
for the CMT-TRIAAL and CMT-TRAUK groups, published online March 9.
-
Pareyson D, Reilly MM, Schenone A, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011, for the CMT-TRIAAL and CMT-TRAUK groups, published online March 9. 10.1016/S1474-4422(11)70025-4.
-
(2011)
Lancet Neurol
-
-
Pareyson, D.1
Reilly, M.M.2
Schenone, A.3
-
7
-
-
16844381836
-
Reliability and validity of the CMT neuropathy score as a measure of disability
-
Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005, 64:1209-1214.
-
(2005)
Neurology
, vol.64
, pp. 1209-1214
-
-
Shy, M.E.1
Blake, J.2
Krajewski, K.3
-
8
-
-
39749139561
-
Neuropathy progression in Charcot-Marie-Tooth disease type 1A
-
Shy ME, Chen L, Swan ER, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008, 70:378-383.
-
(2008)
Neurology
, vol.70
, pp. 378-383
-
-
Shy, M.E.1
Chen, L.2
Swan, E.R.3
-
9
-
-
71049153213
-
The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study
-
Verhamme C, van Schaik IN, Koelman JH, et al. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain 2009, 132:3252-3262.
-
(2009)
Brain
, vol.132
, pp. 3252-3262
-
-
Verhamme, C.1
van Schaik, I.N.2
Koelman, J.H.3
-
10
-
-
0027420097
-
OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction
-
Tugwell P, Boers M OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. J Rheumatol 1993, 20:528-530.
-
(1993)
J Rheumatol
, vol.20
, pp. 528-530
-
-
Tugwell, P.1
Boers, M.2
-
11
-
-
78650170260
-
168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT)
-
Reilly MM, Shy ME, Muntoni F, Pareyson D 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul Disord 2010, 20:839-846.
-
(2010)
Neuromuscul Disord
, vol.20
, pp. 839-846
-
-
Reilly, M.M.1
Shy, M.E.2
Muntoni, F.3
Pareyson, D.4
-
12
-
-
72449140657
-
Diagnosis and new treatments in genetic neuropathies
-
Reilly MM, Shy ME Diagnosis and new treatments in genetic neuropathies. J Neurol Neurosurg Psychiatry 2009, 80:1304-1313.
-
(2009)
J Neurol Neurosurg Psychiatry
, vol.80
, pp. 1304-1313
-
-
Reilly, M.M.1
Shy, M.E.2
-
13
-
-
0036788455
-
PMP22 overexpression causes dysmyelination in mice
-
Robaglia-Schlupp A, Pizant J, Norreel JC, et al. PMP22 overexpression causes dysmyelination in mice. Brain 2002, 125:2213-2221.
-
(2002)
Brain
, vol.125
, pp. 2213-2221
-
-
Robaglia-Schlupp, A.1
Pizant, J.2
Norreel, J.C.3
-
14
-
-
72649095062
-
Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A
-
Saporta MA, Katona I, Lewis RA, et al. Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A. Brain 2009, 132:3263-3273.
-
(2009)
Brain
, vol.132
, pp. 3263-3273
-
-
Saporta, M.A.1
Katona, I.2
Lewis, R.A.3
-
15
-
-
0034255676
-
Clinicoelectrophysiological correlation of extensor digitorum brevis muscle atrophy in children with Charcot-Marie-Tooth disease 1A duplication
-
Berciano J, Garcia J, Calleja J, Combarros O Clinicoelectrophysiological correlation of extensor digitorum brevis muscle atrophy in children with Charcot-Marie-Tooth disease 1A duplication. Neuromuscul Disord 2000, 10:419-424.
-
(2000)
Neuromuscul Disord
, vol.10
, pp. 419-424
-
-
Berciano, J.1
Garcia, J.2
Calleja, J.3
Combarros, O.4
-
16
-
-
0028800889
-
Charcot-Marie-Tooth disease type 1A: morphological phenotype of the 17p duplication versus PMP22 point mutations
-
Gabreëls-Festen AA, Bolhuis PA, Hoogendijk JE, et al. Charcot-Marie-Tooth disease type 1A: morphological phenotype of the 17p duplication versus PMP22 point mutations. Acta Neuropathol 1995, 90:645-649.
-
(1995)
Acta Neuropathol
, vol.90
, pp. 645-649
-
-
Gabreëls-Festen, A.A.1
Bolhuis, P.A.2
Hoogendijk, J.E.3
-
17
-
-
41149124406
-
Lithium delays progression of amyotrophic lateral sclerosis
-
Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Nat Acad Sci USA 2008, 105:2052-2057.
-
(2008)
Proc Nat Acad Sci USA
, vol.105
, pp. 2052-2057
-
-
Fornai, F.1
Longone, P.2
Cafaro, L.3
-
18
-
-
79952739185
-
Lessons learned from Lithium trials in ALS
-
Miller RG, Katz J, Moore D Lessons learned from Lithium trials in ALS. Amyotroph Lateral Scler 2010, 11(suppl 1):63-71.
-
(2010)
Amyotroph Lateral Scler
, vol.11
, Issue.SUPPL. 1
, pp. 63-71
-
-
Miller, R.G.1
Katz, J.2
Moore, D.3
|